Infection Incidence With Upadacitinib in Patients With Rheumatoid Arthritis

Source: Clinical Impact of New Rheumatoid Arthritis Findings From EULAR 2020*
Download Slideset
June 3-6, 2020; Virtual Meeting
In this descriptive analysis, upadacitinib 30 mg was associated with a higher rate of serious and opportunistic infections, including herpes zoster, compared with the 15 mg dose.
Format: Microsoft PowerPoint (.ppt)
File Size: 216 KB
Released: July 7, 2020

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Stanley B. Cohen, MD Released: December 23, 2020

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 18, 2020 Expired: No longer available for credit

From ACR/ARP 2020: expert-authored commentary on tapering RA therapy, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 18, 2020 Expired: No longer available for credit

From ACR/ARP 2020: expert-authored commentary on evaluating RA and the utility of telemedicine, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD William F. C. Rigby, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 18, 2020 Expired: No longer available for credit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings